Budesonide inhalation - AstraZeneca

Drug Profile

Budesonide inhalation - AstraZeneca

Alternative Names: Rhinocort Aqua

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Nasal polyps; Perennial allergic rhinitis; Rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 05 Dec 2016 Cilag completes the agreement with AstraZeneca to acquire budesonide inhalation (Rhinocort Aqua) outside USA
  • 07 Oct 2016 Cilag plans to acquire budesonide nasal (Rhinocort Aqua) outside the US in the fourth quarter of 2016
  • 17 Sep 2009 Launched for Rhinitis in Canada (Intranasal, 64μg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top